Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Common Equity: 2020-2024

Historic Common Equity for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $61.0 million.

  • Mereo BioPharma Group's Common Equity fell 35.76% to $46.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.6 million, marking a year-over-year decrease of 35.76%. This contributed to the annual value of $61.0 million for FY2024, which is 20.64% up from last year.
  • As of FY2024, Mereo BioPharma Group's Common Equity stood at $61.0 million, which was up 20.64% from $50.5 million recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Common Equity registered a high of $118.6 million during FY2021, and its lowest value of -$19.2 million during FY2020.
  • In the last 3 years, Mereo BioPharma Group's Common Equity had a median value of $51.4 million in 2022 and averaged $54.3 million.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 717.05% in 2021, then plummeted by 56.67% in 2022.
  • Mereo BioPharma Group's Common Equity (Yearly) stood at -$19.2 million in 2020, then surged by 717.05% to $118.6 million in 2021, then slumped by 56.67% to $51.4 million in 2022, then dropped by 1.68% to $50.5 million in 2023, then increased by 20.64% to $61.0 million in 2024.